Close Menu
  • Home
  • AI
  • Art & Style
  • Economy
  • Entertainment
  • International
  • Market
  • Opinion
  • Politics
  • Sports
  • Trump
  • US
  • World
What's Hot

Trump says ‘good chance’ of progress in Iran talks. What we know | US-Israel war on Iran News

July 28, 2026

Gen Z bird watching boom | CNN

July 28, 2026

Fish Audio raises $52M seed to build AI voice models for creators and enterprises

July 28, 2026
Facebook X (Twitter) Instagram
Smart Breaking News on AI, Business, Politics & Global Trends | WhistleBuzz
Facebook X (Twitter) Instagram
  • Home
  • AI
  • Art & Style
  • Economy
  • Entertainment
  • International
  • Market
  • Opinion
  • Politics
  • Sports
  • Trump
  • US
  • World
Smart Breaking News on AI, Business, Politics & Global Trends | WhistleBuzz
Home » Stocks with the biggest price movements at noon: ASML, SKHY, SAP, FBRX, BF.B
World

Stocks with the biggest price movements at noon: ASML, SKHY, SAP, FBRX, BF.B

Editor-In-ChiefBy Editor-In-ChiefJuly 28, 2026No Comments3 Mins Read
Share Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email Copy Link
Follow Us
Google News Flipboard
Share
Facebook Twitter LinkedIn Pinterest Email


Check out some of the companies that made the biggest moves midday: ASML — The semiconductor manufacturing equipment maker’s stock fell 8%. The Information reported that China has begun mass production of domestically produced deep ultraviolet chip manufacturing tools. Memory chip stocks — After chipmaker CXMT debuted as a public stock in Shanghai, its stock price rose significantly, soaring more than 466%. SK Hynix stock fell more than 8%, SanDisk stock fell 11%, and Micron Technology stock fell 5%. SAP — Shares of the German software company, whose American depositary receipts are traded on the New York Stock Exchange, rose more than 7% after the company announced in January that it would begin the second round of a 10 billion euro (US$11.37 billion) share buyback, FactSet Street Account Services said. Energy stocks — The group followed oil prices lower after the U.S. and Iran agreed to suspend mutual attacks. Chevron and ExxonMobil shares each fell about 1%. Shares in APA and Devon Energy fell between 1% and 3%. Forte Biosciences — The biotech stock rose about 40% after agreeing to be acquired by the Netherlands’ Argenx for $2.2 billion in cash, or $77 per share. The deal is expected to close in the third quarter and represents a 40% premium to Forte’s closing price of $54.78 on Friday. Argenx’s U.S.-listed shares fell about 2%. Rivian Automotive — The electric car maker’s stock jumped 5% after Piper Sandler upgraded Rivian from neutral to overweight. The company’s $20 price target assumes a 26% upside from Friday’s closing price. Analyst Alexander Potter highlighted Rivian’s recent strengthened delivery guidance and smooth launch of the R2 SUV. Brown-Forman — Shares rose about 4% after the maker of Jack Daniel’s whiskey rejected another unsolicited $32-per-share takeover offer from Sazerac that was first offered earlier this year. The Louisville, Kentucky-based distilling company said the $15 billion bid was not “feasible” and did not align with the board’s “vision for Brown-Forman’s future.” Baker Hughes — Shares rose 6% after Baker Hughes posted better-than-expected earnings and earnings in the second quarter. Chief Executive Officer Lorenzo Simonelli said in a statement that the company expects to reach the midpoint of its full-year forecast thanks to “favorable underlying fundamentals as we continue to operate through the uncertainties in the Middle East.” Amkor Technology — Shares fell 7% as the semiconductor packaging and testing company is scheduled to release quarterly numbers after the market closes. D-Wave Quantum — The company announced a partnership with AT&T on Monday, with plans to use its annealing quantum computer to boost the telecom giant’s AI efforts. D-Wave stock rose 5%, while IonQ and Rigetti Computing stock rose 6% and 7%, respectively. Maplight Therapeutics — Shares of the clinical-stage biotech company fell 68% after results from a Phase 2 trial of its schizophrenia drug showed that once-daily dosing failed to meet primary endpoints and mild side effects occurred more frequently than a placebo. — CNBC’s Darla Mercado, Ananya Chettiar and Fred Imbert contributed reporting



Source link

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Editor-In-Chief
  • Website

Related Posts

BEST: Trump account reaches 7 million subscribers

July 28, 2026

Trader Mike Koo talks about Netflix’s predicament as Hollywood movie ends

July 28, 2026

From ‘oil’ to ‘shock’, here’s what Kalsi traders expect Warsh to say.

July 28, 2026
Add A Comment

Comments are closed.

News

Trump says ‘good chance’ of progress in Iran talks. What we know | US-Israel war on Iran News

By Editor-In-ChiefJuly 28, 2026

US President Donald Trump says Washington is engaged in “very friendly negotiations” with Iran after…

President Trump expresses dissatisfaction with Prime Minister Netanyahu before White House meeting | Donald Trump News

July 28, 2026

Is Prime Minister Netanyahu’s trump card losing power in Israel? |Prime Minister Benjamin Netanyahu News

July 28, 2026
Top Trending

Fish Audio raises $52M seed to build AI voice models for creators and enterprises

By Editor-In-ChiefJuly 28, 2026

The market for AI-generated voice models is huge. Creative use cases require…

Data centers could face temporary power outages to prevent blackouts on the nation’s largest power grid

By Editor-In-ChiefJuly 28, 2026

The nation’s largest power grid is struggling to cope with the onslaught…

This $9 key physically locks your most addictive apps

By Editor-In-ChiefJuly 28, 2026

Screen time apps aren’t effective for many people because they ultimately rely…

Subscribe to News

Subscribe to our newsletter and never miss our latest news

Welcome to WhistleBuzz.com (“we,” “our,” or “us”). Your privacy is important to us. This Privacy Policy explains how we collect, use, disclose, and safeguard your information when you visit our website https://whistlebuzz.com/ (the “Site”). Please read this policy carefully to understand our views and practices regarding your personal data and how we will treat it.

Facebook X (Twitter) Instagram Pinterest YouTube

Subscribe to Updates

Subscribe to our newsletter and never miss our latest news

Facebook X (Twitter) Instagram Pinterest
  • Home
  • Advertise With Us
  • Contact US
  • DMCA Policy
  • Privacy Policy
  • Terms & Conditions
  • About US
© 2026 whistlebuzz. Designed by whistlebuzz.

Type above and press Enter to search. Press Esc to cancel.